Science News: Late Breaking Clinical Trials 2014

Scientific Sessions 2014

November 15–19, 2014
Chicago, Illinois

Sunday's Selected Late Breaking Clinical Trials

Risk and Benefit of Prolonged Dual Antiplatelet Therapy After Drug-eluting Coronary Stents: Primary Endpoint Results from the Dual Antiplatelet Therapy Study
Laura Mauri | Brigham & Women's Hospital Boston, MA

Increased Risk of Ischemic Events Upon Discontinuation of Prasugrel After 12 or 30 Months of Therapy Following Placement of the Taxus Liberté Paclitaxel- Eluting Coronary Stent
Kirk N Garratt | Lenox Hill Heart and Vascular Institute, New York, NY

Randomized, Double Blind Trial of 6 Versus 12 Months Of Dual Antiplatelet Therapy After DES-Implantation (ISAR-SAFE)
Stefanie Schüpke (née Schulz) | Deutsches Herzzentrum München, Muenchen, Germany

Is 6 Months DAPT Post Coronary Stenting Non Inferior To 24 Months? The Italic/ Italic+ Randomized Trial. Results of the One Year Primary Endpoint
Martine Gilard | University of Brest, Brest Cedex, France

Monday's Selected Late Breaking Clinical Trials

IMPROVE-IT Trial: A Comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes After Acute Coronary Syndromes
Christopher P Cannon | Brigham and Women's Hospital Boston, MA

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Patients With Multiple Atherosclerotic Risk Factors: A Randomized Controlled Trial
Kazuyuki Shimada | Shin-Oyama City Hospital, Tochigi, Japan

Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using Coronary CT Angiography: Primary Results of FACTOR-64, a Randomized Controlled Trial
Joseph B Muhlestein | Intermountain Medical Center, University of Utah, Murrah, UT

ODYSSEY ALTERNATIVE: Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm
Patrick M Moriarty | University of Kansas Medical Center, Kansas City, KS

Tuesday's Selected Late Breaking Clinical Trials

Randomized Trial of Atenolol Versus Losartan in Children and Young Adults With Marfan Syndrome
Ronald V Lacro | Boston Children's Hospital, Boston, MA

A Randomized Trial of Losartan In Hypertrophic Cardiomyopathy - The INHERIT Trial
Anna Axelsson | Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

The Incidence of Infective Endocarditis in England is Increasing - An Assessment of the Impact of Cessation of Antibiotic Prophylaxis Using Population Statistics
Martin H Thornhill | The School of Clinical Dentistry, The University of Sheffield, Sheffield, United Kindom

The Surgical Treatment of Moderate Ischemic Mitral Regurgitation: A Randomized Clinical Trial From The Cardiothoracic Surgical Trials Network
Robert E Michler | Montefiore-Einstein Heart Center, New York, NY

Wednesday's Selected Late Breaking Clinical Trials

Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-eluting Stents and Bare Metal Stents - Main Results of a Prospective Randomized Trial
Christoph A Kaiser | University Hospital Basel, Basel, Switzerland

Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent
Dean J. Kereiakes | The Christ Hospital Heart and Vascular Center/ The Lindner Research Center, Cincinnati, Ohio

A Randomised Controlled Trial of Oxygen Therapy in Acute St-segment Elevation Myocardial Infarction: The Air Versus Oxygen in Myocardial Infarction (AVOID) Study
Dion Stub | Baker IDI Heart and Diabetes Institute, St Paul's Hospital, Vancouver, BC, Canada

Developing Regional STEMI Systems of Care: Final Results of the Mission: Lifeline STEMI ACCELERATOR Study
Matthew W Sherwood | Duke University, Durham, NC